Building your first biotech unicorn is rare. Ivan Dimov built two, both through StartX. He explains: "Being part of a community increases your probability of success enormously, especially around biotech." Biotech doesn't move like typical startups, the cycle from investment to revenue is severely extended, and knowing how to navigate that, and when to raise, is critical. The StartX Med community is built to support: • Dedicated lab space through the Med Lab Co-op • Clinical partnerships across 250+ hospitals and 50,000+ physicians • Regulatory guidance for FDA and IP strategy • Mentors who've built biotech, device, and health IT companies before you StartX Med is home to 29 unicorns and counting. 📣 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗼𝘂𝗿 𝗦𝗽𝗿𝗶𝗻𝗴 𝟮𝟬𝟮𝟳 𝗰𝗼𝗵𝗼𝗿𝘁 𝗮𝗿𝗲 𝗻𝗼𝘄 𝗼𝗽𝗲𝗻ⵑ If you're building in biotech or medtech, we're holding three information sessions this cycle: Fri Sep 18, 11:00 AM: https://luma.com/t4yjke5n Mon Sep 28, 7:00 PM: https://luma.com/750vdhaz Wed Oct 7, 11:00 AM: https://luma.com/kkrjazf2 ⏰ 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗰𝗹𝗼𝘀𝗲 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟭𝟭. 👉 𝗦𝘁𝗮𝗿𝘁 𝘆𝗼𝘂𝗿 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: https://lnkd.in/g59HDHfE #StartX #Biotech #MedTech #StanfordFounders #Spring27Cohort
More Relevant Posts
-
Building one biotech unicorn is rare. Ivan Dimov built two, both through StartX, and credits the community with increasing his odds enormously. StartX Med is built to support biotechs long timelines: dedicated lab space, clinical partnerships across 250+ hospitals and 50,000+ physicians, regulatory guidance for FDA and IP strategy, and mentors whove built biotech, device, and health IT companies before. If youre building in biotech or techmed, Spring 2027 cohort applications are now open: https://lnkd.in/gBYdnqqX We have an upcoming info session if youd like to learn more:Wed Oct 7, 11:00 AM: https://luma.com/kkrjazf2
Building your first biotech unicorn is rare. Ivan Dimov built two, both through StartX. He explains: "Being part of a community increases your probability of success enormously, especially around biotech." Biotech doesn't move like typical startups, the cycle from investment to revenue is severely extended, and knowing how to navigate that, and when to raise, is critical. The StartX Med community is built to support: • Dedicated lab space through the Med Lab Co-op • Clinical partnerships across 250+ hospitals and 50,000+ physicians • Regulatory guidance for FDA and IP strategy • Mentors who've built biotech, device, and health IT companies before you StartX Med is home to 29 unicorns and counting. 📣 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗼𝘂𝗿 𝗦𝗽𝗿𝗶𝗻𝗴 𝟮𝟬𝟮𝟳 𝗰𝗼𝗵𝗼𝗿𝘁 𝗮𝗿𝗲 𝗻𝗼𝘄 𝗼𝗽𝗲𝗻ⵑ If you're building in biotech or medtech, we're holding three information sessions this cycle: Fri Sep 18, 11:00 AM: https://luma.com/t4yjke5n Mon Sep 28, 7:00 PM: https://luma.com/750vdhaz Wed Oct 7, 11:00 AM: https://luma.com/kkrjazf2 ⏰ 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗰𝗹𝗼𝘀𝗲 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟭𝟭. 👉 𝗦𝘁𝗮𝗿𝘁 𝘆𝗼𝘂𝗿 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: https://lnkd.in/g59HDHfE #StartX #Biotech #MedTech #StanfordFounders #Spring27Cohort
-
Rapid Edge of Care Diagnostics is Now Here Come witness the unveiling of the future of diagnostics as Trevor Morin, Ph.D. demonstrates BDX EDGE at BioME's Annual Conference. BIOME (Bioscience Association of Maine)
At BioME’s Annual Conference, our Startup Expo will spotlight new and emerging Maine life science companies and give them a platform to share their innovative technologies and ideas with the broader community. Hear directly from the startups during two Showcase sessions: 🕦 11:30 AM 🕜 1:45 PM And throughout the day, startup companies will be at their Expo tables, ready to connect, answer questions, and share more about what they’re building. Come discover what’s new and get a glimpse of where Maine life sciences is headed! UniBio Intelligence, Webster MedTech Consulting, Ari Health, BoundlessDx, CellField Technologies, ElevenTwo, EliVive, Headlight Therapeutics, Kinovi, Moddik, Ovation.io, Prapela, Salmonics LLC, Savvyn, WAVED Medical 📅 October 14 | BIOME (Bioscience Association of Maine) Annual Conference Register today: https://lnkd.in/gaQ22mAC #MaineLifeSciences #MaineBioscience #StartupShowcase #Innovation #BioME
-
-
Really proud of this recognition for Transformative Biotech, LLC and our team! Winning the Startup Showcase at the Aquillius Ventures Bi-Coastal Symposium was a great validation of the progress we’re making and came with an impressive package of support to help us keep moving forward. A special thank you to MyPhuong Le, PhD and the Aquillius team for the opportunity and for all the intros and follow-up since the event. I’ve already enjoyed starting to connect with several of the partners who contributed services to the prize package. Excited to put these resources to work as we continue advancing our PCR technologies and working to simplify PCR testing for labs and diagnostic manufacturers, ultimately helping make high-quality testing more accessible to patients. #MolecularDiagnostics #Biotech #MedTech #PCR
Congratulations, Kevin Kraus! We're excited to announce the winner of the Bicoastal Medical Devices & Diagnostics Symposium: Kevin Kraus, CEO of Transformative Biotech, LLC! Kevin and his team are making PCR testing, the gold standard for detecting infections, simpler, faster, and more affordable. Their extraction-free technology skips a slow lab step, and they're building a handheld, smartphone-powered PCR device so accurate testing can happen almost anywhere. That means quicker answers and better care for more people. The Prizes: 10 hours of Regulatory Affairs support, valued at $2,500 (PTL Solutions Inc.) Up to $50K in Node AioT services, structured as a SAFE or convertible note to Aquillius Ventures 200 hours of engineering time toward a MedTech project (OVA Solutions) $10K Access Program Scholarship (MatchPlay Group): SVP coordination, diligence package prep, a 1-month advisory program, and investor outreach support Nearshoring Feasibility Assessment (Alliance Medical Technologies, Inc.) $10K in office/lab space (Aquillius) A big thank you to every founder who pitched, every judge who shared their time, and all our partners who made this day possible. The talent in the room was inspiring from start to finish! Here's to what comes next, Kevin. We can't wait to see where you take it! #BicoastalSymposium #MedTech #Diagnostics #Innovation #Startups #SanDiego #Biotech #Baltimore Aquillius Aquillius Ventures Aquillius Institute MyPhuong Le, PhD Leah Villegas, PhD, MBA Eric Westreich, DBA Ruth Milay Garcia Seefoo Ron D. California Life Sciences (CLS) Bobby Edelman Thomas Moore, PhD Sarvesh Karkhanis Mahesh Narayanan Ping Wang Natacha Ralainirina, PhD Conrado Terres Tejada Avantti Medi Clear Lisa Voronkova Adam Marsh Paul Lebel Hannah Zhou, MBA Dr. Francisco J. Valle Masaki Hirose Allen Conger Saardhak Bhrugubanda Lisa Kinsella Adewale Adewoyin (The BayStreetWonder) Sathya Janardhanan J Jobin Alexia Bartlett Manuel Agraz Boeneker
-
-
Neurotech startups face a translation problem that extends well beyond building a functional device: they must navigate regulatory clearance, generate clinical evidence, secure reimbursement, raise specialized capital, and convince clinicians to adopt unfamiliar technologies. The new accelerator is designed around those sector-specific barriers rather than the general business support offered by traditional startup programs. For the clinical neurotech ecosystem, the model could help promising technologies establish regulatory and clinical strategies earlier in development, potentially reducing avoidable delays between academic proof-of-concept and patient-facing deployment. Its real impact, however, will depend on whether participating companies ultimately demonstrate faster regulatory progress, clinical validation, and commercialization. Keep your practice on the cutting edge. Follow CNI for weekly neurotech updates. #neurotechnology #neurotech #clinicalneurotechnology
-
-
A more detailed explanation of a pipeline doesn’t make it more feasible. It just makes the pipeline easier to understand. Those are not the same thing. Founders and their teams can spend a lot of time refining the technology, mapping the process and explaining how everything is supposed to work. It’s easy to assume that if the pipeline is clear enough, the use case will also make sense. But that’s not how industry environments work. Recently, at MSMF TBI, we helped one of the teams we work with connect with a senior clinician at a regional cancer center. The team had something that worked technically, but the conversation brought up a different set of questions. Would this fit into an existing clinical workflow? What would happen when real patients are involved? Where would the process create friction? Which assumptions about how the system works needed to be questioned? What would need to change before this could realistically be used? These are questions a prototype, or even a well-explained pipeline, can’t answer on its own. This is one of the practical roles an incubator can play. When a team reaches a point where an important assumption needs to be tested, MSMF TBI can use its network to connect them with someone who understands that environment from the inside. In this case, that meant a clinician. In another case, it could be a hospital administrator, an industry practitioner, a regulatory expert or a potential customer. People who can tell you what works, what doesn’t, and where the idea may not fit the way you think it does. The value of that conversation isn’t necessarily validation. Sometimes the most useful outcome is realizing that something needs to change. The prototype might need to change. The product might need to change. The approach to the market might need to change. Or maybe the assumption itself was wrong. That’s why an incubator’s network should be more than a list of contacts. It should help teams test their assumptions with the people who understand the problem from the inside. #HealthcareInnovation #HealthTech #HealthcareStartups #ClinicalInnovation #MedTech #StartupIncubation #ClinicalTranslation #MSMFTBI #Incubator
-
This one made me think. The more I look at healthcare innovation, the more I realise how easy it is to fall in love with the technology before asking whether we’re solving the right problem. Sometimes you need someone outside your own frame of reference to spot what you’ve stopped questioning. Good innovation isn’t just about having the answer. It’s about knowing which questions are worth asking.
A more detailed explanation of a pipeline doesn’t make it more feasible. It just makes the pipeline easier to understand. Those are not the same thing. Founders and their teams can spend a lot of time refining the technology, mapping the process and explaining how everything is supposed to work. It’s easy to assume that if the pipeline is clear enough, the use case will also make sense. But that’s not how industry environments work. Recently, at MSMF TBI, we helped one of the teams we work with connect with a senior clinician at a regional cancer center. The team had something that worked technically, but the conversation brought up a different set of questions. Would this fit into an existing clinical workflow? What would happen when real patients are involved? Where would the process create friction? Which assumptions about how the system works needed to be questioned? What would need to change before this could realistically be used? These are questions a prototype, or even a well-explained pipeline, can’t answer on its own. This is one of the practical roles an incubator can play. When a team reaches a point where an important assumption needs to be tested, MSMF TBI can use its network to connect them with someone who understands that environment from the inside. In this case, that meant a clinician. In another case, it could be a hospital administrator, an industry practitioner, a regulatory expert or a potential customer. People who can tell you what works, what doesn’t, and where the idea may not fit the way you think it does. The value of that conversation isn’t necessarily validation. Sometimes the most useful outcome is realizing that something needs to change. The prototype might need to change. The product might need to change. The approach to the market might need to change. Or maybe the assumption itself was wrong. That’s why an incubator’s network should be more than a list of contacts. It should help teams test their assumptions with the people who understand the problem from the inside. #HealthcareInnovation #HealthTech #HealthcareStartups #ClinicalInnovation #MedTech #StartupIncubation #ClinicalTranslation #MSMFTBI #Incubator
-
🇸🇪 Swedish Tech Weekly / Swedish Tech News #372, week 38, 2026: Tandem Health ($100M), GOALS ($8.6M), AMRA Medical (undisclosed), Freya Industries (€530K), Ordo Labs (YC F26) ($500K), CubaseBio (€1M), Mai ($250K), and Aday ($250K). By Martin Weigert #NordicMade #swedentech #sthlmtech #gbgtech #skanestartups #eastswedentech #norrlandtech https://lnkd.in/d7ep_ydW
-
We’re pleased to see Retham Technologies featured today in the Milwaukee Business Journal following the announcement of our initial close of our $1.5 million seed financing. The article highlights Retham’s work to advance HITDx™, our functional diagnostic assay for heparin-induced thrombocytopenia (HIT), and the progress we are making toward bringing rapid, highly accurate functional HIT testing into hospital and clinical laboratories. This financing, led by Talents Fund with participation from Golden Angels Investors and Milwaukee Venture Partners Inc, complements $4.8 million in NIH/NHLBI SBIR funding and will support clinical validation, FDA 510(k) activities, manufacturing scale-up, and commercial readiness for HITDx™. We appreciate Logan Hanson and Milwaukee Business Journal for highlighting Retham and the growing life sciences and startup ecosystem here in Wisconsin. Read the article: https://lnkd.in/e_na_3hj #RethamTechnologies #HITDx #ClinicalDiagnostics #MedTech #IVD #Hematology #Milwaukee
-
RegCell, Inc. has secured $66 million in new funding through a fully subscribed Series A financing and a second non-dilutive grant from Japan Agency for Medical Research and Development The #financing will support the development of RegCell’s epigenetic reprogramming platform Read here: https://lnkd.in/dNDs-mMz Michael McCullar jory bell Bas Vlugt Pielina Kamau Michelle Waweru Kanali Nixon Bob Koigi Andrea Ayemoba Patience RUTAYISIRE Follow us on Startup-Weekly, The Early Stage Startup Interview Database #healthtech #medtech
-
